Bayer and Janssen sue Breckenridge over Xeralto
Bayer and Janssen Pharmaceuticals have sued Breckenridge Pharmaceutical for allegedly infringing two patents related to the deep vein thrombosis treatment drug Xeralto (rivaroxaban).
The patents, US numb ers 7,157,456 and 7,592,339, belong to Bayer and are sublicensed to Janssen.
The case was filed in the US District Court for the District of Delaware on Monday, July 25.
Bayer and Janssen targeted Breckenridge after it filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration seeking approval to produce a generic version of Xeralto in the US.
According to the complaint, Breckenridge intends to release the generic as soon as it receives approval of the ANDA and before the expiration of the patents.
In the complaint, Bayer said: “Unless Breckenridge is enjoined from infringing … actively inducing infringement and contributing to the infringement by others … plaintiffs will suffer irreparable injury.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk